Abstract
Kirsten rat sarcoma (KRAS) mutations are the most common oncogenic driver in non-squamous Non-Small Cell Lung Cancer (NSCLC), occurring in approximately 25-30% of cases. Despite recent advent of novel selective KRAS inhibitors, the majority of KRAS-mutant patients still receive either immunotherapy alone or in combination with chemotherapy as upfront treatment in the routine practice. This study investigated real-world clinical features and survival outcomes of patients with advanced NSCLC harboring KRAS mutation who received standard first-line therapies in Italy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
